The purpose is to see if a drug, remibrutinib 25 mg twice a day, is safe and effective in treatment of peanut, milk or egg allergy.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide), South Carolina, Virginia
Edwin Kim
Pediatrics - Allergy Immunology and Rheumatology
Clinical or Medical
Interventional
Allergy
25-1171
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
